Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Abnormal Vision in Childhood Can Affect Brain Functions

By University of Waterloo | October 15, 2018

A research team has discovered that abnormal vision in childhood can affect the development of higher-level brain areas responsible for things such as attention.

The researchers from the University of Waterloo, University of British Columbia, and the University of Auckland uncovered differences in how the brain processes visual information in patients with various types of lazy eye. In doing so, they are the first to demonstrate that the brain can divert attention away from a lazy eye when both eyes are open.

“Current treatments for lazy eye primarily target the early stages of visual processing within the brain,” said Ben Thompson, a professor in Waterloo’s School of Optometry and Vision Science.“The results from this study show us that new treatments should also target higher-level processes such as attention.”

Lazy eye, known as amblyopia, is a loss of vision that originates in the brain, typically when a child develops an eye turn (strabismic type) or a substantial difference in refractive error between the eyes (anisometropic type). The unequal input causes the brain to ignore information from the weaker eye during brain development. Conventionally, eyecare practitioners treated the different types of lazy eye similarly, primarily because the visual impairments experienced appeared to be the same.

In this study lead researcher, Amy Chow, and her colleagues asked patients to pay attention to a specific set of dots among a group of distracting dots, all moving on a computer screen. However, the tracked dots were only visible in one eye (the weaker eye) while the distracting dots were visible only to the other eye (the stronger eye).

For people with normal vision as well as those with anisometropic amblyopia, showing different images between the two eyes didn’t matter. Both groups were able to overcome the distracting interference and track the dots successfully. Patients with strabismic amblyopia, on the other hand, were unable to direct their attention to the target dots when they were visible to only the weaker eye.

“One of the underlying reasons why some people with lazy eye have poor vision comes down to how the brain suppresses an eye,” said Chow, a Ph.D. student at the School of Optometry and Vision Science at Waterloo. “The poorer-seeing eye is open, the retina is healthy and sending information through to the brain, yet that information does not reach conscious awareness as the brain chooses not to use it.”

About thirty-five thousand Canadians – one percent of the population – have strabismic amblyopia. The condition can be corrected in childhood, but treatment efficacy can be highly variable. These findings are a stepping stone in developing better treatments of lazy eye.

Their paper, Dichoptic Attentive Motion Tracking is Biased Toward the Nonamblyopic Eye in Strabismic Amblyopia, appears this month in a special issue of the journal Investigative Ophthalmology and Visual Science. The project was supported by the Natural Sciences and Engineering Research Council of Canada.


Filed Under: Neurological Disease

 

Related Articles Read More >

Novo Nordisk in the Drug Discovery & Development Pharma 50
Novo Alzheimer’s trial disappoints as amycretin shines
Shifting mindsets all around: clinical thinking about Alzheimer’s disease moves from symptoms treatment toward earlier intervention and prevention
Quanterix VP: Why biomarkers are no longer supplemental
Texas sues Kenvue claiming it hid link between Tylenol and autism
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE